Oleoylethanolamide‐induced anorexia in rats is associated with locomotor impairment

The endogenous peroxisome proliferator‐activated receptor alpha ( PPAR ‐ α ) agonist Oleoylethanolamide ( OEA ) inhibits eating in rodents, mainly by delaying the onset of meals. The underlying mechanisms of OEA ‐induced anorexia, however, remain unclear. Animals treated with high OEA doses were shown to display signs of discomfort and impaired locomotion. Therefore, we first examined whether the impaired locomotion may contribute to OEA 's anorectic effect. Second, it is controversial whether abdominal vagal afferents are necessary for OEA 's anorectic effect. Thus, we explored alternative peripheral neural pathways mediating IP OEA 's anorectic effect by performing a celiac‐superior mesenteric ganglionectomy ( CGX ) or a subdiaphragmatic vagal deafferentation ( SDA ) alone or in combination. Exogenously administered OEA at a commonly used dose (10 mg/kg BW , IP ) concurrently reduced food intake and compromised locomotor activity. Attempts to dissociate both phenomena using the dopamine D2/D3 receptor agonist Quinpirole (1 mg/kg BW , SC ) failed because Quinpirole antagonized both, OEA ‐induced locomotor impairment and delay in eating onset. CGX attenuated the prolongation of the latency to eat by IP OEA , but neither SDA nor CGX prevented IP OEA ‐induced locomotor impairment. Our results indicate that IP OEA 's anorectic effect may be secondary to impaired locomotion rather than due to physiological satiety. They further confirm that vagal afferents do not mediate exogenous OEA 's anorectic effects, but suggest a role for spinal afferents in addition to an alternative, nonneuronal signaling route.